Known targets — ChEMBL curated mechanism
The experimentally established mechanism targets of Serlopitant. The predicted profile below is derived independently by chemical similarity — agreement is a validation signal, a miss is honest.
Predicted protein targets (top 10)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | TACR1 known ✓ | P25103 | 20/20 | 1.00 |
| ▸ | TACR2 | P21452 | 2/20 | 1.00 |
| ▸ | CYP3A4 | P08684 | 1/20 | 1.00 |
| ▸ | CYP2C8 | P10632 | 1/20 | 1.00 |
| ▸ | CYP2D6 | P10635 | 1/20 | 1.00 |
| ▸ | CYP2C9 | P11712 | 1/20 | 1.00 |
| ▸ | TACR3 | P29371 | 1/20 | 1.00 |
| ▸ | CYP2C19 | P33261 | 1/20 | 1.00 |
| ▸ | KCNH2 | Q12809 | 1/20 | 0.58 |
| ▸ | NR1I2 | O75469 | 1/20 | 0.57 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Serlopitant SCHEMBL3183159 | 1.00 | TACR1 (1.00) | TACR1TACR2CYP3A4CYP2C8CYP2D6 | |
| Serlopitant SCHEMBL16333766 | 1.00 | TACR1 (1.00) | TACR1TACR2CYP3A4CYP2C8CYP2D6 | |
| Serlopitant SCHEMBL16280735 | 1.00 | TACR1 (1.00) | TACR1TACR2CYP3A4CYP2C8CYP2D6 | |
| Serlopitant SCHEMBL12646287 | 1.00 | TACR1 (1.00) | TACR1TACR2CYP3A4CYP2C8CYP2D6 | |
| Serlopitant SCHEMBL24067973 | 1.00 | TACR1 (1.00) | TACR1TACR2CYP3A4CYP2C8CYP2D6 | |
| Serlopitant SCHEMBL3184271 | 1.00 | TACR1 (1.00) | TACR1TACR2CYP3A4CYP2C8CYP2D6 | |
| Serlopitant SCHEMBL23883105 | 1.00 | TACR1 (1.00) | TACR1TACR2CYP3A4CYP2C8CYP2D6 | |
| SCHEMBL13531608 | 0.95 | TACR1 (0.91) | TACR1TACR2CYP3A4CYP2C8CYP2D6 | |
| SCHEMBL16280639 | 0.95 | TACR1 (0.91) | TACR1TACR2CYP3A4CYP2C8CYP2D6 | |
| SCHEMBL16353223 | 0.95 | TACR1 (0.91) | TACR1TACR2CYP3A4CYP2C8CYP2D6 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 38 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-4125875-A1 | AN NK-1 RECEPTOR ANTAGONIST FOR TREATING A DISEASE SELECTING FROM SEPSIS, SEPTIC SHOCK,, ACUTE RESPIRATORY DISTRESS SYNDROME (ARDS) OR MULTIPLE ORGAN DYSFUNCTION SYNDROME (MODS) | NeRRe Therapeutics Limited (GB) | 2023-02-08 | — | — | EP | disclosed |
| WO-2022253945-A1 | PHARMACEUTICAL DOSAGE FORMS COMPRISING 3-(5-METHYL-1,3-THIAZOL-2-YL)-5-[(3R)-TETRAHYDROFURAN-3-YLOXY]-N-{(1R)-1-[2-(TRIFLUOROMETHYL)PYRIMIDIN-5-YL]ETHYL}-BENZAMIDE | BAYER AKTIENGESELLSCHAFT (DE) | 2022-12-08 | — | — | WO | disclosed |
| EP-3990453-A1 | ANALOGUES OF 3-(5-METHYL-1,3-THIAZOL-2-YL)-N-{(1R)-1-[2-(TRIFLUORO-METHYL)PYRIMIDIN-5-YL]ETHYL}BENZAMIDE | Bayer Aktiengesellschaft (DE) | 2022-05-04 | — | — | EP | disclosed |
| CN-114026086-A | Analogs of 3- (5-methyl-1, 3-thiazol-2-yl) -N- { (1R) -1- [2- (trifluoromethyl) pyrimidin-5-yl ] ethyl } benzamide | 拜耳公司 | 2022-02-08 | — | — | CN | disclosed |
| WO-2021198255-A1 | AN NK-1 RECEPTOR ANTAGONIST FOR TREATING A DISEASE SELECTING FROM SEPSIS, SEPTIC SHOCK,, ACUTE RESPIRATORY DISTRESS SYNDROME (ARDS) OR MULTIPLE ORGAN DYSFUNCTION SYNDROME (MODS) | NERRE THERAPEUTICS LIMITED (GB) | 2021-10-07 | — | — | WO | disclosed |
| US-20210169848-A1 | USE OF NEUROKININ-1 ANTAGONISTS TO TREAT PRURITUS | VYNE THERAPEUTICS INC (US) | 2021-06-10 | — | — | US | disclosed |
| WO-2020260463-A1 | ANALOGUES OF 3-(5-METHYL-1,3-THIAZOL-2-YL)-N-{(1R)-1-[2-(TRIFLUORO-METHYL)PYRIMIDIN-5-YL]ETHYL}BENZAMIDE | BAYER AKTIENGESELLSCHAFT (DE) | 2020-12-30 | — | — | WO | disclosed |
| US-20200306224-A1 | USE OF NK-1 RECEPTOR ANTAGONIST SERLOPITANT IN PRURITUS | VYNE THERAPEUTICS INC. | 2020-10-01 | — | — | US | disclosed |
| US-10702499-B2 | Use of NK-1 receptor antagonists in pruritus | MENLO THERAPEUTICS INC. (US) | 2020-07-07 | — | — | US | disclosed |
| US-10617671-B2 | Use of NK-1 receptor antagonist serlopitant in pruritus | MENLO THERAPEUTICS INC. (US) | 2020-04-14 | — | — | US | disclosed |
| US-9474741-B2 | Use of NK-1 receptor antagonists in pruritus | MENLO THERAPEUTICS INC. (US) | 2016-10-25 | — | — | US | disclosed |
| US-20160279100-A1 | USE OF NK-1 RECEPTOR ANTAGONISTS IN PRURITUS | VYNE THERAPEUTICS INC. (F/K/A MENLO THERAPEUTICS INC. AND SUCCESSOR-IN-INTEREST TO VYNE PHARMACEUTICALS LTD., F/K/A FOAMIX PHARMACEUTICALS LTD.) | 2016-09-29 | — | — | US | disclosed |
| US-9381188-B2 | Use of NK-1 receptor antagonists in pruritus | Tigercat Pharma, Inc. (US) | 2016-07-05 | — | — | US | disclosed |
| US-20160143882-A1 | USE OF NK-1 RECEPTOR ANTAGONIST SERLOPITANT IN PRURITUS | VYNE THERAPEUTICS INC. (F/K/A MENLO THERAPEUTICS INC. AND SUCCESSOR-IN-INTEREST TO VYNE PHARMACEUTICALS LTD., F/K/A FOAMIX PHARMACEUTICALS LTD.) | 2016-05-26 | — | — | US | disclosed |
| US-20160038462-A1 | USE OF NK-1 RECEPTOR ANTAGONISTS IN PRURITUS | VYNE THERAPEUTICS INC. (F/K/A MENLO THERAPEUTICS INC. AND SUCCESSOR-IN-INTEREST TO VYNE PHARMACEUTICALS LTD., F/K/A FOAMIX PHARMACEUTICALS LTD.) | 2016-02-11 | — | — | US | disclosed |
| US-9198898-B2 | Use of NK-1 receptor antagonists in pruritus | Tigercat Pharma, Inc. (US) | 2015-12-01 | — | — | US | disclosed |
| US-20150057255-A1 | USE OF NK-1 RECEPTOR ANTAGONISTS IN PRURITUS | VYNE THERAPEUTICS INC. (F/K/A MENLO THERAPEUTICS INC. AND SUCCESSOR-IN-INTEREST TO VYNE PHARMACEUTICALS LTD., F/K/A FOAMIX PHARMACEUTICALS LTD.) | 2015-02-26 | — | — | US | disclosed |
| WO-2014209962-A1 | USE OF NK-1 RECEPTOR ANTAGONIST SERLOPITANT IN PRURITUS | Tigercat Pharma, Inc. (US) | 2014-12-31 | — | — | WO | disclosed |
| US-20140378521-A1 | USE OF NK-1 RECEPTOR ANTAGONISTS IN PRURITUS | VYNE THERAPEUTICS INC. (F/K/A MENLO THERAPEUTICS INC. AND SUCCESSOR-IN-INTEREST TO VYNE PHARMACEUTICALS LTD., F/K/A FOAMIX PHARMACEUTICALS LTD.) | 2014-12-25 | — | — | US | disclosed |
| US-8906951-B1 | Use of NK-1 receptor antagonists in pruritus | Tigercat Pharma, Inc. (US) | 2014-12-09 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (9 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-10702499-B2 | Use of NK-1 receptor antagonists in pruritus | TACR1, CYSLTR1, HRH3 | TACR1 1/4885TACR2 12/4885CYP3A4 774/4885 |
| US-20210169848-A1 | USE OF NEUROKININ-1 ANTAGONISTS TO TREAT PRURITUS | TACR1, BDKRB2, KLKB1 | TACR1 1/4885TACR2 5/4885CYP3A4 3161/4885 |
| US-20150057255-A1 | USE OF NK-1 RECEPTOR ANTAGONISTS IN PRURITUS | TACR1, CYSLTR1, HRH3 | TACR1 1/4885TACR2 12/4885CYP3A4 774/4885 |
| US-10617671-B2 | Use of NK-1 receptor antagonist serlopitant in pruritus | TACR1, CYSLTR1, NPSR1 | TACR1 1/4885TACR2 8/4885CYP3A4 849/4885 |
| US-20160038462-A1 | USE OF NK-1 RECEPTOR ANTAGONISTS IN PRURITUS | TACR1, CYSLTR1, HRH3 | TACR1 1/4885TACR2 12/4885CYP3A4 774/4885 |
| US-20140378521-A1 | USE OF NK-1 RECEPTOR ANTAGONISTS IN PRURITUS | MRGPRX1, MRGPRX2, TACR1 | TACR1 3/4885TACR2 9/4885CYP3A4 1779/4885 |
| US-20160143882-A1 | USE OF NK-1 RECEPTOR ANTAGONIST SERLOPITANT IN PRURITUS | TACR1, CYSLTR1, NPSR1 | TACR1 1/4885TACR2 8/4885CYP3A4 849/4885 |
| US-20200306224-A1 | USE OF NK-1 RECEPTOR ANTAGONIST SERLOPITANT IN PRURITUS | TACR1, CYSLTR1, NPSR1 | TACR1 1/4885TACR2 8/4885CYP3A4 849/4885 |
| US-20160279100-A1 | USE OF NK-1 RECEPTOR ANTAGONISTS IN PRURITUS | TACR1, CYSLTR1, HRH3 | TACR1 1/4885TACR2 12/4885CYP3A4 774/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.